Skip to main content
PMC home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2005 Mar;66(2):80–95. doi: 10.1016/j.curtheres.2005.04.004

Status of lipid-lowering therapy prescribedbased on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: A study of the Japan Lipid Assessment Program (J-LAP)

Tamio Teramoto 1, Atsunori Kashiwagi 2, Hiroshi Mabuchi 3, J-LAP Investigators *,**
PMCID: PMC3964576  PMID: 24672115

Abstract

Background:

In its 1997 Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults and subsequent revisions, the Japan10 Atherosclerosis Society (JAS) recommends serum lipid management goals (SLMGs) based on a coronary heart disease (CHD) risk classification. A literature search revealed that the status of lipid-lowering therapy based on the current JAS recommendations in Japan has not been assessed.

Objective:

The aim of this study was to evaluate the efficacy of current lipid-lowering 10 regimens, and to provide the best possible therapeutic strategies for patients with hyperlipidemia by identifying risk factors for the development of CHD, based on the current JAS recommendations.

Methods:

This multicenter, retrospective study was conducted using data 10 from patients under the care of physicians at 12,500 randomly selected institutions across Japan. Physicians received a survey concerning lipid-lowering therapy, on which each physician provided data from 10 consecutive adult patients with hyperlipidemia who had been prescribed lipid-lowering therapy for at least 3 months before the survey was administered, and who were undergoing routine follow-up on an outpatient basis. Physicians provided patients' demographic and clinical data, including JAS-defined CHD risk classification coronary risk factors and pre- and posttreatment (after ≥3 months) serum lipid levels, and the types and dosages of drugs in patients' current and prior treatment regimens. These data were used to assess the efficacy of lipid-lowering regimens and rates of patients achieving the SLMGs recommended by the JAS.

Results:

A total of 2540 physicians participated in the survey, and data from 10 24,893 Japanese patients (mean [SD] age, 65.8 [10.5] years) with hyperlipidemia were included in the study. Patients with familial hyperlipidemia (845/24,893 [3.4%]) were excluded from most of the analyses, leaving 24,048 patients with primary hyperlipidemia. The most prevalent coronary risk factors included age (21,902 [91.1%]), hypertension (14,275 [59.4%]), diabetes mellitus type 2 and/or impaired glucose tolerance (6346 [26.4%]), and smoking (3841 [16.0%]). A total of 20,948 patients (87.1%) had a CHD risk classification of B (ie, ≥1 coronary risk factor but no history of CHD). At the time of the survey, the lipid-lowering regimens of 22,080 patients (91.8%) included a statin. The rates of achievement of SLMGs were as follows: total cholesterol (TC), 12,659/23,840 patients (53.1%); low-density lipoprotein cholesterol (LDL-C), 14,025/22,121 (63.4%); high-density lipoprotein cholesterol, 19,702/21,279 (92.6%); and triglycerides (TG), 14,892/ 23,569 (63.2%). TC and LDL-C goals were achieved by most patients (≥61.1%) in risk categories A, B1, and B2 (ie, 0–2 coronary risk factors; low to moderate risk) but by a low percentage of patients (≤45.4%) in risk categories B3, B4, and C (ie, ≥3 coronary risk factors or history of CHD; high risk). In the high-risk group (n = 10,515), the TC goal was achieved by 4059 patients (38.6%). The TC and LDL-C goals were achieved by significantly higher percentages of patients prescribed atorvastatin (5133/7928 [64.7%] and 5487/7426 [73.9%], respectively) compared with the rates of patients prescribed any other statin at the recommended starting doses (all, P < 0.05).

Conclusions:

The results of this study of Japanese patients undergoing lipid-lowering 10 therapy for the prevention of CHD, prescribed based on the recommendations in the JAS guideline, suggest insufficient reduction of TC, LDL-C, and TG in patients at high risk for CHD and the need for more aggressive lipid-lowering therapy in such patients.

Key words: J-LAP, hyperlipidemia, lipid-lowering therapy, guidelines, achievement rates for management goals, HMG-CoA reductase inhibitors, statins

Full Text

The Full Text of this article is available as a PDF (1,015.3 KB).

References

  • 1.Kannel W.B., Castelli W.P., Gordon T., McNamara P.M. Serum cholesterol, lipoproteins, and risk of coronary heart disease. The Framingham Study. Ann Intern Med. 1971;74:1–12. doi: 10.7326/0003-4819-74-1-1. [DOI] [PubMed] [Google Scholar]
  • 2.Stamler J., Wentworth D., Neaton J.D. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT) JAMA. 1986;256:2823–2828. [PubMed] [Google Scholar]
  • 3.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383–1389. [PubMed] [Google Scholar]
  • 4.Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS) Circulation. 1998;97:1440–1445. doi: 10.1161/01.cir.97.15.1440. [DOI] [PubMed] [Google Scholar]
  • 5.Matsuzaki M., Kita T., Mabuchi H., J-LIT Study Group, Japan Lipid Intervention Trial Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy inJapanese patients with hypercholesterolemia. Circ J. 2002;66:1087–1095. doi: 10.1253/circj.66.1087. [DOI] [PubMed] [Google Scholar]
  • 6.Mabuchi H., Kita T., Matsuzaki M., J-LIT Study Group, Japan Lipid Intervention Trial Large scale cohort study of the relationship between serum cholesterol concentration and coronary events with low-dose simvastatin therapy inJapanese patients with hypercholesterolemia and coronary heart disease: Secondary prevention cohort study of the Japan Lipid Intervention Trial (J-LIT) Circ J. 2002;66:1096–1100. doi: 10.1253/circj.66.1096. [DOI] [PubMed] [Google Scholar]
  • 7.Hata Y., Mabuchi H., Saito Y. Guideline for diagnosis and treatment of hyperlipidemia in adults [in Japanese] Domyakukoka. 1997;25:1–34. [Google Scholar]
  • 8.Hata Y., Mabuchi H., Saito Y., Working Committee on JAS Guideline for Diagnosis and Treatment of Hyperlipidemias Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults. J Atheroscler Thromb. 2002;9:1–27. doi: 10.5551/jat.9.1. [DOI] [PubMed] [Google Scholar]
  • 9.Saito Y. Editorial: Guidelines for Diagnosis and Treatment of Atherosclerotic Cardiovascular Diseases 2002. J Atheroscler Thromb. 2004;11:101–103. [PubMed] [Google Scholar]
  • 10.Mabuchi H., Inazu A., Higashikata T. The current status of medicinal therapy for hyperlipidemia-Kanazawa Lipid Assessment Survey (K-LAS) [in Japanese] Prog Med. 2000;20:1629–1639. [Google Scholar]
  • 11.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the NationalCholesterol Educational Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497. doi: 10.1001/jama.285.19.2486. [DOI] [PubMed] [Google Scholar]
  • 12.Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502. [PubMed] [Google Scholar]
  • 13.Pearson T.A., Laurora I., Chu H., Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160:459–467. doi: 10.1001/archinte.160.4.459. [DOI] [PubMed] [Google Scholar]
  • 14.Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) JAMA. 1993;269:3015–3023. [PubMed] [Google Scholar]
  • 15.Muls E., De Backer G., De Bacquer D. LIPI-WATCH, a Belgian/Luxembourg survey on achievement of European Atherosclerosis Society lipid goals. Clin Drug Invest. 2000;19:219–229. [Google Scholar]
  • 16.International Task Force on the Prevention of Coronary Heart Disease Recommendation of the European Atherosclerosis Society prepared by the International Task Force for Prevention of Coronary Heart Disease. Nutr Metab Cardiovasc Dis. 1992;2:113–156. [Google Scholar]
  • 17.Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7–22. [Google Scholar]
  • 18.Sever P.S., Dahlof B., Poulter N.R., ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet. 2003;361:1149–1158. doi: 10.1016/S0140-6736(03)12948-0. [DOI] [PubMed] [Google Scholar]
  • 19.Bellosta S., Ferri N., Arnaboldi L. Pleiotropic effects of statins in atherosclerosis and diabetes. Diabetes Care. 2000;23(Suppl 2):1372–1378. [PubMed] [Google Scholar]
  • 20.Ito H., Ouchi Y., Ohashi Y. A comparison of low versus standard dose pravastatin therapy for the prevention of cardiovascular events in the elderly: The pravastatin anti-atherosclerosis trial in the elderly (PATE) J Atheroscler Thromb. 2001;8:33–44. doi: 10.5551/jat1994.8.33. [published correction appears in J Atheroscler Thromb. 2001;8:following 100] [DOI] [PubMed] [Google Scholar]
  • 21.Horiuchi H., Matsuzawa Y., Mabuchi H. Strategy for treating elderly Japanese with hypercholesterolemia. Geriatr Gerontol Int. 2004;4:151–157. [Google Scholar]
  • 22.Dawber T.R., Kannel W.B., Revotskie N. Some factors associated with the development of coronary heart disease: Six years' follow-up experience in the Framingham Study. Am J Public Health. 1959;49:1349–1356. doi: 10.2105/ajph.49.10.1349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Kannel W.B., Dawber T.R., Kagan A. Factors of risk in the development of coronary heart disease-six year follow-up experience: The Framingham Study. Ann Intern Med. 1961;55:33–50. doi: 10.7326/0003-4819-55-1-33. [DOI] [PubMed] [Google Scholar]
  • 24.Kannel W.B., Dawber T.R., Friedman G.D. Risk factors in coronary heart disease. An evaluation of several serum lipids as predictors of coronary heart disease; The Framingham Study. Ann Intern Med. 1964;61:888–899. doi: 10.7326/0003-4819-61-5-888. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES